Phosphodiesterase type 5 (PDE5) inhibitors are widely used for erectile dysfunction and pulmonary arterial hypertension, but their side effects vary in ways that are often misunderstood. This literature review summarises how differences in enzyme selectivity (which PDE targets a drug hits most strongly) and pharmacokinetics (how long it stays in the body) shape real-world tolerability across sildenafil, vardenafil, tadalafil and avanafil.
Tadalafil stands out because it has a much longer half-life than sildenafil or vardenafil, creating a longer treatment window and supporting once-daily dosing. However, its distinct selectivity profile also helps explain why its side effects can look different. While sildenafil and vardenafil have more clinically relevant activity at PDE6 (linked to visual disturbances), tadalafil has minimal PDE6 activity but more cross-reactivity with PDE11, which is associated with a higher rate of back pain and myalgia in some users. Avanafil shows the highest PDE5 selectivity in vitro, which may contribute to a favourable tolerability profile.
Overall, the evidence suggests that “best” is rarely about potency alone. Choosing between PDE5 inhibitors should consider side effect risk, patient comorbidities (such as visual or musculoskeletal issues), and whether a daily or on-demand regimen is preferred. This review aims to support safer, more individualised prescribing and clearer patient counselling at courierpharmacy.co.uk.
-
Product on sale
Tadalafil 5mg tabletsPrice range: £9.99 through £94.99
Introduction and mechanism of action
Phosphodiesterase type 5 (PDE5) inhibitors have revolutionised the treatment of erectile dysfunction and pulmonary arterial hypertension since the introduction of sildenafil in 1998 [1]. These drugs work by inhibiting the enzyme PDE5, which normally hydrolyses cyclic guanosine monophosphate (cGMP) to GMP [2]. By blocking this degradation, cGMP accumulates in vascular smooth muscle cells, leading to vasodilation and increased blood flow [3]. Among the most commonly used PDE5 inhibitors are sildenafil (Viagra), vardenafil (Levitra), tadalafil (Cialis), and avanafil, each with distinct pharmacological profiles [4].
Tadalafil distinguishes itself from other PDE5 inhibitors through its unique pharmacokinetic and pharmacodynamic characteristics. The most notably distinguishing feature of tadalafil is its exceptionally long half-life of approximately 17.5 hours (range 11.5 to 29.6 hours), compared to approximately 4 hours for sildenafil and vardenafil [5]. This extended duration provides a longer therapeutic window, allowing for once-daily dosing and spontaneous sexual activity within a 36-hour window, which differs significantly from the on-demand use typical of shorter-acting inhibitors [4].
PDE5 enzyme selectivity and off-target effects
The differential selectivity of PDE5 inhibitors for various phosphodiesterase isoforms represents a fundamental source of their varying side effect profiles [4]. Although all PDE5 inhibitors are relatively selective for PDE5, they exhibit variable inhibitory potencies against other phosphodiesterase family members, which mediates their side effects [6]. This cross-reactivity with non-target enzymes is the primary driver of adverse effects associated with these medications.
Avanafil exhibits the highest selectivity for PDE5 among currently available inhibitors [6]. In vitro studies demonstrate that avanafil shows greater than 1,000-fold selectivity for PDE5 over PDE1, PDE6, and PDE11 compared to other inhibitors. This exceptional selectivity translates to fewer colour vision disturbances and minimal hemodynamic side effects in clinical trials, with musculoskeletal and hemodynamic adverse events occurring in less than 2% of patients. The superior selectivity profile of avanafil also contributes to its favourable tolerability, though it maintains comparable efficacy to other agents.
Sildenafil presents a different selectivity profile, with significant inhibitory activity against PDE6, which is located exclusively in retinal photoreceptors [7]. This cross-reactivity is directly responsible for the characteristic visual side effects associated with sildenafil, including transient alterations in colour vision (blue-green colour discrimination, particularly), light sensitivity, and blurred vision occurring in 3-11% of users [8]. The inhibition of PDE6 interferes with the normal visual transduction cascade in photoreceptors, producing these temporary ophthalmologic effects.
Vardenafil, while chemically distinct from sildenafil, retains similar cross-reactivity patterns with PDE6, producing comparable visual disturbances [4]. Additionally, vardenafil inhibits cardiac potassium channels, leading to QT interval prolongation in some patients, a unique concern among PDE5 inhibitors. This represents an additional safety concern not present with other agents in the class.
Tadalafil demonstrates a markedly different selectivity pattern compared to other PDE5 inhibitors [9]. Rather than showing substantial inhibition of PDE6, tadalafil exhibits significant cross-reactivity with PDE11, a phosphodiesterase family member distributed in cardiac myocytes, skeletal muscle, pituitary tissue, heart, and testes. Structural analysis reveals that specific amino acid residues in the M-loop region of the binding site determine tadalafil’s selectivity for PDE5 over PDE6, distinct from the residues mediating vardenafil binding [9]. Specifically, replacing human PDE5 residues with corresponding class-specific cone PDE6 residues dramatically reduces tadalafil affinity for PDE6 while leaving vardenafil affinity unchanged, demonstrating fundamentally different binding mechanisms.
Side effects associated with tadalafil
Musculoskeletal adverse effects
The most characteristic and prominent side effect specific to tadalafil is back pain and myalgia (muscle aches and joint pains), which occur at significantly higher rates than with other PDE5 inhibitors [10]. This adverse effect is directly attributable to tadalafil’s lower selectivity for PDE11, which is expressed in skeletal muscle tissue. The incidence of back pain with tadalafil ranges from approximately 5-20% in clinical trials, substantially higher than the 2-4% observed with sildenafil [5]. The mechanism appears to involve PDE11 inhibition disrupting normal cAMP regulation in muscle tissue, though the exact pathophysiology remains incompletely understood.
In a comprehensive meta-analysis comparing tadalafil with sildenafil, tadalafil demonstrated higher rates of myalgia and back pain while sildenafil showed higher rates of flushing [10]. This pharmacodynamic distinction underscores how selective inhibition patterns produce divergent adverse event profiles. Interestingly, regular daily dosing with tadalafil has been associated with improved side effect tolerability over time compared to on-demand dosing, suggesting potential adaptation to continuous PDE11 inhibition [11].
Cardiovascular and hemodynamic effects
Unlike vardenafil, tadalafil does not produce clinically significant QT interval prolongation, representing a safety advantage [4]. The hemodynamic effects of tadalafil, including blood pressure reduction and hypotension risk, are generally comparable to other agents when appropriately dosed and not co-administered with nitrates. Notably, tadalafil does not lower systemic blood pressure in clinical trials as substantially as some other PDE5 inhibitors, particularly at therapeutic doses.
Visual and neurological safety
A significant advantage of tadalafil over sildenafil and vardenafil is the virtual absence of visual side effects [4]. Because tadalafil exhibits minimal cross-reactivity with PDE6, colour vision disturbances, photophobia, and other ophthalmologic effects associated with PDE6 inhibition are not clinically significant problems [10]. This represents a major therapeutic advantage for patients requiring long-term therapy or those with pre-existing visual concerns.
General adverse events
The most commonly reported adverse effects of tadalafil include headache, flushing, dyspepsia, and nasal congestion—vasodilatory effects shared with other PDE5 inhibitors [5]. These side effects are generally mild, reversible, and tend to diminish with continued use. In comprehensive analyses of PDE5 inhibitors in patients with erectile dysfunction after nerve-sparing radical prostatectomy, tadalafil demonstrated the lowest treatment-emergent adverse event rates among PDE5 inhibitors studied [11].
Comparative adverse event profiles
Comparative efficacy and safety meta-analysis
A direct comparison meta-analysis of tadalafil versus sildenafil revealed similar efficacies in treating erectile dysfunction; however, the safety profiles differed significantly [10]. Sildenafil was associated with increased rates of visual changes and higher overall adverse event rates, whereas tadalafil showed higher myalgia and back pain but lower flushing rates. Importantly, patients receiving tadalafil demonstrated improved psychological outcomes compared to sildenafil, likely related to reduced treatment-emergent adverse events and more predictable pharmacokinetics.
Pharmacokinetic influence on side effect expression
The extended half-life of tadalafil creates a distinct pharmacokinetic signature that influences side effect manifestation. The pharmacokinetic profile produces more uniform drug levels compared to the peak-and-trough pattern of on-demand agents [4]. The clinical consequence includes more predictable side effect timing and potentially better tolerability with chronic administration.
Mechanism of selective adverse effect profiles
The fundamental principle explaining differential side effect profiles among PDE5 inhibitors relates to their relative selectivity ratios [12]. The potency ratio for inhibiting PDE5 versus off-target isoforms determines the likelihood of isoform-specific adverse effects. For sildenafil, the relatively weak selectivity against PDE6 compared to its potent PDE5 inhibition results in measurable PDE6 inhibition at therapeutic doses, producing visual side effects. Sildenafil’s Gln817 residue is critical for binding to PDE5, sildenafil, and vardenafil, but specific substitutions dramatically alter selectivity for different isoforms [12].
Tadalafil’s distinct amino acid interactions with the PDE5 catalytic site confer its selectivity pattern [9]. The presence of specific residues in the M-loop region determines its lower affinity for PDE6 compared to other agents. Conversely, tadalafil’s affinity for PDE11 is substantially higher than that of sildenafil or vardenafil, explaining the preferential association with musculoskeletal effects.
Duration of action and pharmacokinetic implications
The extended half-life of tadalafil offers distinct advantages beyond convenience in dosing schedules [5]. Because tadalafil maintains effective plasma concentrations for extended periods, peak plasma concentrations are lower relative to on-demand agents, potentially reducing concentration-dependent adverse effects. This is evidenced by lower rates of acute hemodynamic side effects with tadalafil compared to higher-dose on-demand regimens of shorter-acting inhibitors [4].
Steady-state is attained within 5 days of once-daily tadalafil administration, with mild accumulation consistent with its terminal half-life. This linear pharmacokinetics and minimal accumulation suggest predictable side effect patterns after the initial dosing period. Food has negligible effects on tadalafil bioavailability, contributing to its favorable pharmacokinetic profile.
Emerging evidence on long-acting PDE5 inhibitor selectivity
Recent evidence suggests that long half-life PDE5 inhibitors, particularly tadalafil, may confer metabolic benefits distinct from short-acting agents. A systematic review and meta-analysis demonstrated metabolic advantages of longer-acting inhibitors in patients with diabetes. These findings suggest that the continuous cGMP elevation achieved with tadalafil’s extended half-life may provide cardiometabolic benefits beyond immediate vasodilation.
Clinical implications for patient selection and dosing
The distinct side effect profiles of PDE5 inhibitors have important implications for individualised treatment selection [4]. Patients with pre-existing visual concerns or colour vision abnormalities should avoid sildenafil and vardenafil in favour of tadalafil or avanafil. Conversely, patients with pre-existing musculoskeletal conditions or back pain may tolerate sildenafil or vardenafil better than tadalafil.
The choice between on-demand and daily dosing with PDE5 inhibitors also influences side effect expression [4]. Daily low-dose tadalafil has been shown to improve erectile function over time while potentially reducing the incidence and severity of acute adverse effects compared to higher-dose on-demand regimens. This suggests that chronic, low-level PDE5 inhibition may be better tolerated than intermittent high-level inhibition.
Off-label uses and side effect considerations
Beyond erectile dysfunction and pulmonary arterial hypertension, PDE5 inhibitors have been investigated for numerous off-label indications, including benign prostatic hyperplasia, lower urinary tract symptoms, and systemic sclerosis-related Raynaud’s phenomenon. In such clinical applications, tadalafil demonstrates efficacy with adverse events primarily manifesting expected vasodilatory side effects of headache and flushing. The absence of PDE6-related visual effects and the relatively low incidence of back pain in specific patient populations highlight the favourable tolerability profile for longer-term dosing.
Conclusions
Tadalafil’s side effect profile differs fundamentally from other PDE5 inhibitors due to its distinct selectivity pattern, characterised by minimal PDE6 cross-reactivity and higher PDE11 inhibition [9]. While this results in the absence of visual side effects and lower rates of visual disturbances compared to sildenafil and vardenafil, tadalafil is uniquely associated with back pain and myalgia through PDE11 inhibition in skeletal muscle. The extended half-life of tadalafil provides steady-state cGMP levels that may produce fewer acute hemodynamic effects while potentially conferring metabolic benefits.
The pharmacological understanding of PDE5 inhibitor selectivity demonstrates that drug selectivity ratios directly determine which adverse effects manifest clinically [5]. Avanafil offers superior overall selectivity and the most favourable adverse event profile among approved agents, albeit with potential cost and access limitations [6]. Sildenafil and vardenafil, while effective, carry the burden of PDE6-related visual side effects due to their cross-reactivity patterns [4]. Tadalafil occupies a middle ground, providing excellent visual safety and cardiovascular tolerability at the expense of musculoskeletal side effects driven by PDE11 inhibition.
Clinicians must consider individual patient factors—including comorbidities, visual concerns, musculoskeletal health, and preference for dosing frequency—when selecting among PDE5 inhibitors [4]. The field continues to evolve with the development of next-generation agents exhibiting even greater selectivity, potentially minimising side effects while maintaining therapeutic efficacy. Understanding the mechanistic basis for differential side effect profiles enables personalised therapeutic approaches that optimise efficacy while minimising adverse events for individual patients.
Disclaimer: This information is for education only and isn’t a substitute for personal medical advice. Always follow your prescriber’s instructions.
References:
[4] W. Smith, I. McCaslin, A. Gökçe, S. H. Mandava, L. Trost, and W. J. g. Hellstrom, “PDE5 inhibitors: considerations for preference and long-term adherence,” International Journal of Clinical Practice, Jul. 2013, https://onlinelibrary.wiley.com/doi/10.1111/ijcp.12074
[5] A. D. Seftel, “Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles,” Clinical Cardiology, Apr. 2004, https://onlinelibrary.wiley.com/doi/10.1002/clc.4960271305
[6] R. Wang et al., “Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability,” The Journal of Sexual Medicine, Jul. 2012, https://www.sciencedirect.com/science/article/abs/pii/S1743609515340674
[7] E. Ausó, V. Gómez?Vicente, and G. Esquiva, “Visual Side Effects Linked to Sildenafil Consumption: An Update,” Biomedicines, Mar. 2021, https://www.mdpi.com/2227-9059/9/3/291
[8] F. Azzouni and K. A. Samra, “Are Phosphodiesterase Type 5 Inhibitors Associated with Vision-Threatening Adverse Events? A Critical Analysis and Review of the Literature,” The Journal of Sexual Medicine, Jul. 2011, https://academic.oup.com/jsm/article/8/10/2894/6980061
[9] K. B. Cahill, J. Quade, K. Carleton, and R. Cote, “Identification of Amino Acid Residues Responsible for the Selectivity of Tadalafil Binding to Two Closely Related Phosphodiesterases, PDE5 and PDE6*,” Journal of Biological Chemistry, Oct. 2012, doi: 10.1074/jbc.M112.389189.
[10] B. Gong et al., “Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis,” International Urology and Nephrology, Jul. 2017,https://link.springer.com/article/10.1007/s11255-017-1644-5
[11] S. Qiu et al., “Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer,” Scientific Reports, Sep. 2016, https://www.nature.com/articles/srep32853
[12] R. Zoraghi, J. Corbin, and S. Francis, “Phosphodiesterase-5 Gln817 Is Critical for cGMP, Vardenafil, or Sildenafil Affinity,” Journal of Biological Chemistry, Mar. 2006, doi: 10.1074/jbc.M510372200.
